Skip to content

These are the free online talks we have scheduled for 2022, every first Monday of the month (16:30 -17:30 CET).
Subscribe to our newsletter to stay up to date! We also have the a nice PDF-poster for you to print and hang above your desk.

We are also already working on the schedule of 2023. If you have have a suggestion for a speaker you can contact us.

Monday October 3rd
Prof. James MacCabe
“Treatment resistant psychosis: is evidence-based medicine failing?”

After an intercalated BSc in Psychology and Basic Medical Sciences, Professor MacCabe qualified in medicine at the University of London in 1995 and completed his basic and higher specialist training in Psychiatry at the Maudsley Hospital from 1997 to 2004. He obtained a joint MRC/Department of Health Special Training Fellowship in Health of the population research in 2004, in collaboration with the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, Stockholm. He obtained an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine in 2006 and a PhD in 2008. In 2009 he was awarded a Clinical Senior Lectureship by the Higher Education Funding Council for England. He was awarded a personal chair as Professor of Epidemiology and Therapeutics at King’s College London in 2019. 
Professor MacCabe has been honorary consultant psychiatrist at the National Psychosis Unit since 2005, where he is responsible for treating inpatients with severe psychosis and conducting clinical trials. Prof MacCabe serves on the Board of Trustees of the mental health charity, SANE.
Professor MacCabe’s research in treatment refractory schizophrenia personalised medicine mirrors his clinical work, and is geared towards helping people whose psychosis has not responded to standard antipsychotic treatment.  His research includes work on the epidemiology, genetics and neurochemistry underlying treatment refractory schizophrenia, and identifying biomarkers that may be used in personalised medicine. Much of his research is conducted in collaboration with UK and international partners. 
Monday November 7th
Prof. Arianna Di Florio
“Postpartum psychosis and bipolar disorder: two different disorders or the same?”

Arianna is a researcher and clinical psychiatrist. Psychiatric disorders associated with changes in female sex hormones, such as those associated with the menstrual cycle, childbirth and transition to menopause, are a major public health issue and represent a unique opportunity to study the complex interplay between gender, sex and mental states. In my role at Cardiff University, I have set up the Reproductive Neuroscience Clinical and Research Programme to study how genetic and environmental markers can help identify women at risk of psychiatric disorders in relation to changes in sex hormones and improve the current approach to diagnosis, prevention and treatment. The programme includes the European Research Council funded project “Genetic Architecture Of Sex Steroid-related Psychiatric Disorders” (GASSP), the first molecular genetic study of the psychiatric sensitivity to sex hormone changes.
At the MRC Centre for Neuropsychiatric Genetics and Genomics at Cardiff University I lead the bipolar disorder genomics research group. Together with the Bipolar Disorder Research Network, the centre has collected the largest cohort of people with bipolar disorder in the world and has made important contributions to the understanding of the genetic susceptibility underpinning the disorder.
Monday December 5th
Prof. Klaas Enno Stephan
Topic and bio to be announced
Date to be announced
Prof. Rene Kahn
Topic to be announced

Dr. René Kahn is Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai since 2017. After completing medical school in the Netherlands, he was trained as a psychiatrist and neurologist in Utrecht and Amsterdam, respectively. He subsequently completed his
psychiatry residencies at Mount Sinai Hospital and then worked as Chief of the psychiatry research unit at the Bronx VA. In 1993 he moved back to Utrecht to become to Chair of Psychiatry at the University hospital, going on to lead the Brain Center Rudolf Magnus, which combines research in basic neuroscience, psychiatry and neurology. Dr. Kahn has published over 950 research papers with a Web of Science H index of 107. He has been continuously funded for over 25 years by NIMH, the EU, the Stanley Foundation, and other organizations. He has served on neuroscience grant review boards in the Netherlands as well as those of the United Kingdom and Germany. He received several honors, such as a Fulbright Scholarship, membership of the Royal Netherlands Academy of Arts and Sciences, the ECNP Neuropsychopharmacology Award, an honorary doctorate at Semmelweis University in Budapest, Hungary and the lifetime achievement award of the Netherlands Psychiatric Association. He was knighted in the Netherlands in 2018. He served as Treasurer and Vice-President of the European College of Neuropsychopharmacology and as President of The Schizophrenia International Research Society. He is a fellow of the American College of Neuropsychopharmacology.

Previous talks

Monday February 7th
Prof. Quentin Huys
“Computational Psychiatry: can computers outperform psychiatrists?”

Professor Quentin Huys is a clinician and associate professor of Computational Psychiatry at the Department of Psychiatry, Max Planck UCL Centre and Computational Psychiatry and Ageing Research at University College London. His research interests are computational psychiatry, with particular focus on developing computational tools to improve patient outcomes in depression and addictive disorders; complex decision-making and learning, and computational models of emotion.
Monday March 7th
Dr. Markku Lahteenvuo
“Antipsychotic efficacy in the real world”

Markku Lähteenvuo currently works as a chief of forensic psychiatry at Niuvanniemi hospital, the largest state operated forensic psychiatric hospital in Finland. In addition to his clinical work, he has authored several publications on the real-world effectiveness of psychopharmacological therapies for depression, bipolar disorder and schizophrenia. He is also involved in projects related to the genetics of psychiatric disorders and treatment response.
Monday April 4th
Dr. Olav Smeland
“Understanding the landscape of shared genetic determinants of mental disorders: where will this bring psychiatrists and researchers?”

Olav B Smeland is a medical doctor from Norway with a PhD in neuroscience. He works as a psychiatrist at Oslo University Hospital and is a researcher at the Norwegian Centre for Mental Disorders Research (NORMENT). His main area of research interest is uncovering the genetic risk architecture of severe mental disorders such as schizophrenia and bipolar disorder. In particular he focuses on investigating the shared genetic risk between mental disorders and related traits and diseases.
Monday July 4th
Prof. Christoph Correll
“What’s New in Psychopharmacology in 2022”

Christoph U. Correll is Professor of Psychiatry at The Zucker School of Medicine at Hofstra/Northwell, New York, USA, and also Professor and Chair of the Department of Child and Adolescent Psychiatry, Charité University Medicine, Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City. Since 1997, he has been working and conducting research in New York, USA, and since 2017 he is also working in Germany again.  
 
Professor Correll focuses on the identification and treatment of youth and adults with severe mental illness, clinical trials, epidemiology, psychopharmacology, meta-analyses, and the interface between physical health and mental health.  
He has authored or co-authored over 700 journal articles that have been cited more than 49.000 times and received over 40 research awards for his work. 
Since 2014, the beginning of this metric, he has been listed every year by Clarivate/Web of Science as one of the “most influential scientific minds” and “top 1% cited scientists in the area of psychiatry”.
Monday September 5th
Dr. Heidi Taipale
“Real-world evidence on antipsychotic doses for schizophrenia”

Dr. Heidi Taipale is a Senior Researcher at Karolinska Institutet, Stockholm, Sweden, working in the field of psychiatric epidemiology. She is an Academy Research Fellow at Niuvanniemi Hospital, Kuopio, Finland, working in research on the effectiveness of pharmacotherapy for schizophrenia. 
She has a title of Docent in pharmacoepidemiology and is a Doctor of Science in pharmacy. Her areas of interest and work include the real-world effectiveness of pharmacotherapies in psychiatric disorders, adverse outcomes associated with pharmacotherapies, and register-based psychiatric epidemiology. She has strong focus on developing new and improved methods for register-based research, especially for deriving estimates of medication use from large datasets. She has published more than 160 original works and has over 4000 recorded citations listed in the Google Scholar.